ReviewFrontiers in oncology2025
Rewiring tumor visibility: The immunopeptidome as a dynamic interface between antigen processing, microenvironmental stress, and immune recognition.
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Peptide Arrays as Tools for Unraveling Tumor Microenvironments and Drug Discovery in Oncology.Cells · 2026Review
- Functionalized nanomedicines for co-targeting of multiple pathways to efficiently treat thyroid cancer: prospects and challenges.Frontiers in pharmacology · 2026Review
- Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion.Cancer communications (London, England) · 2026Review
- Protein quality control and antigen presentation in the development of hepatitis B-related hepatocellular carcinoma.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor immunopeptidome dictates whether malignant cells remain visible or invisible to immune surveillance, yet its regulation extends far beyond canonical antigen processing. Here, we synthesize recent insights into how proteasomes, immunoproteasomes, transporter associated with antigen processing (TAP), endoplasmic reticulum aminopeptidase (ERAP), and alternative pathways collectively shape peptide presentation, and how tumor-intrinsic rewiring intersects with microenvironmental stressors such as hypoxia, acidity, and epithelial-mesenchymal transition (EMT). We highlight post-translationally modified ligands as a qualitatively distinct class of tumor antigens, expanding the therapeutic landscape. Across various cancers, the immunoproteasome emerges as both a biomarker and a barometer, with prognostic and predictive value contingent upon the immune context. This duality highlights the necessity for context-aware therapeutic strategies, encompassing selective immunoproteasome modulation, TAP2-based biomarkers, and post-translational modification (PTM)-directed vaccines. Framing the immunopeptidome as a dynamic and rewritable interface provides both mechanistic insight into immune escape and a roadmap for precision immuno-oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.